Roche Holding AG (OTCMKTS:RHHBY) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 771,200 shares, a drop of 30.0% from the November 30th total of 1,101,400 shares. Based on an average daily volume of 1,087,100 shares, the days-to-cover ratio is presently 0.7 days.
Shares of Roche stock opened at $51.78 on Friday. The business’s fifty day moving average price is $50.22 and its two-hundred day moving average price is $48.85. The company has a quick ratio of 0.91, a current ratio of 1.24 and a debt-to-equity ratio of 0.27. Roche has a 1-year low of $39.80 and a 1-year high of $52.47.
Institutional investors and hedge funds have recently bought and sold shares of the company. Ancora Advisors LLC raised its stake in shares of Roche by 262.0% in the 2nd quarter. Ancora Advisors LLC now owns 905 shares of the company’s stock worth $43,000 after buying an additional 655 shares in the last quarter. Vigilant Capital Management LLC raised its stake in shares of Roche by 94.4% in the 3rd quarter. Vigilant Capital Management LLC now owns 972 shares of the company’s stock worth $44,000 after buying an additional 472 shares in the last quarter. IFP Advisors Inc raised its stake in shares of Roche by 42.0% in the 3rd quarter. IFP Advisors Inc now owns 2,787 shares of the company’s stock worth $128,000 after buying an additional 824 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new stake in shares of Roche in the 2nd quarter worth $156,000. Finally, Amundi acquired a new position in shares of Roche in the 2nd quarter worth $216,000. 0.33% of the stock is currently owned by institutional investors.
Several brokerages recently commented on RHHBY. Zacks Investment Research downgraded Roche from a “buy” rating to a “hold” rating and set a $51.00 target price on the stock. in a report on Friday, October 22nd. JPMorgan Chase & Co. raised their target price on Roche from CHF 360 to CHF 390 in a report on Tuesday. Citigroup began coverage on Roche in a report on Wednesday, December 22nd. They set a “buy” rating on the stock. Finally, Morgan Stanley reiterated an “equal weight” rating on shares of Roche in a report on Wednesday, October 13th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $162.47.
Roche Company Profile
Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized & point of care solutions, molecular diagnostics, tissue diagnostics & diabetes care.